



(51) International Patent Classification:

C07D 403/14 (2006.01)	A61P 13/12 (2006.01)
C07D 401/14 (2006.01)	A61P 15/00 (2006.01)
C07D 405/14 (2006.01)	A61P 25/06 (2006.01)
C07D 409/14 (2006.01)	A61P 25/08 (2006.01)
C07D 413/14 (2006.01)	A61P 25/16 (2006.01)
C07D 417/14 (2006.01)	A61P 25/18 (2006.01)
A61K 31/445 (2006.01)	A61P 25/20 (2006.01)
A61K 31/497 (2006.01)	A61P 25/24 (2006.01)
A61K 31/506 (2006.01)	A61P 25/28 (2006.01)
A61K 31/53 (2006.01)	A61P 25/32 (2006.01)
A61P 1/04 (2006.01)	A61P 25/36 (2006.01)
A61P 1/12 (2006.01)	A61P 29/00 (2006.01)
A61P 3/04 (2006.01)	A61P 35/00 (2006.01)
A61P 9/12 (2006.01)	A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2017/017408

(22) International Filing Date:

10 February 2017 (10.02.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/294,940	12 February 2016 (12.02.2016)	US
62/336,102	13 May 2016 (13.05.2016)	US

(71) Applicants: **ASTRAZENECA AB** [SE/SE]; SE-151 85, Södertälje (SE). **EOLAS THERAPEUTICS, INC.** [US/US]; 7445 Trigo Lane, Carlsbad, CA 92009 (US).

(72) Inventors: **KAMENECKA, Theodore, M.**; 50 Stoney Drive, Palm Beach Gardens, FL 33410 (US). **HOLENZ, Jörg**; 921 Main Street, Bolton, MA 01740 (US). **WESO-**

LOWSKI, Steven; 18 School Street Ext., Natick, MA 01760 (US). **HE, Yuanjun**; 10842 Magnolia St., Palm Beach Gardens, FL 33418 (US). **BÜRLI, Roland**; Medimmune Limited, Aaron Klug Building, Granta Park, Cambridge CB21 6GH (GB).

(74) Agents: **VARMA, Anita** et al.; White & Case LLP, 75 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS

(57) Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.